9. ANTIGENIC CLASSIFICATION
• Antigenic Nature of Ribonucleoprotein
• M protein
• 3 types – A,B,C
• Antigenic variation of HA & NAAg – Subtypes
• HA – 15 (H1-H15), NA – 9 ( N1-N9)
• Human – H1-H3, N1-N2
• Non human virus – Pandemic by assortment
10. ANTIGENIC STRUCTURE
• Ribonucleoprotein – RNP – Specific for A,B,C
• Matrix (M) Protein – Type specific
M1, M2
• Haemagglutinin (HA) – Strain specific
Antigenic variation
HA 1, HA 2
Triangular spike
Aggregation of RBC
11. • Neuraminidase (NA) – Strain specific
Surface
Mushroom spike
Destroys RBC Rs –
Release virion from
infected cell
15. ANTIGENIC DRIFT
• Minor Ag changes in HA/NA/ both
• Gradual
• Regular Intervals
• Mutation in HA/NA genes
• New Ag – related to old
• Epidemics
16.
17. ANTIGENIC SHIFT
• Major changes in HA (2-3), NA (1-3)
• New subtype ( Unrelated to old virus )
• Unlikely due to Mutation
• Gene assortment (Recombination )
• Previous Virus Ab cant neutralise new Virus
• Major epidemics , Pandemics
26. ISOLATION OF VIRUS
• Initial 2-3 days
• Throat garglings
• Amniotic cavity / human embryo kidney / Monkey
kidney
• Incubate in eggs for 3 days – Amniotic to Allantoic
• Hemagglutination
• Strains types Identified by antisera
• Subtypes - HAI
27. Haemagglutination test and haemagglutination inhibition test.
The serum from pig "A" contains no antibodies to influenza, which is
why haemagglutination occurs. The serum from pig "B" contains
influenza antibodies, so agglutination is inhibited.
28. The basis of HI assay - antibodies to influenza virus will prevent
attachment of the virus to red blood cells.
Therefore hemagglutination is inhibited when antibodies are present.
The highest dilution of serum that prevents hemagglutination is called
the HI titre
29. SEROLOGY
• CFT
• HAI
• 4 fold rise in titre of Ab between convalascnt
and Acute phase
Results of a haemagglutination inhibition test. The antibody titer is 1:80.
30. IMMUNITY
• 1 strain attack – 1- 2 years protection
• Doctrine of Original Antigenic Sin
When the body first
encounters an infection it
produces effective
antibodies against its
dominant antigens and
thus eliminates the
infection. But when it
encounters the same
infection, at a later
evolved stage, with a
new dominant antigen,
with the original antigen
now being recessive, the
immune system will still
produce the former
antibodies against this
old "now recessive
antigen" and not develop
new antibodies against
the new dominant one,
this results in the
production of ineffective
antibodies and thus a
weak immunity.
31. EPIDEMIOLOGY
• Airborne
• Type C – Endemic
• Type B – Sporadic , Epidemic
• Type A – Pandemics
• Winter/ Monsoon
• WHO – surveillance - ? – Pandemics
• Spanish Flu – 20 million deaths 1918